Biostem Technologies Inc (BSEM)

$5.00 +0.75 (17.65%)
Market Cap 79.42M
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio 5.01
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 169,953
Avg Vol 68,362
Day's Range N/A - N/A
Shares Out 16.79M
Stochastic %K 57%
Beta -0.37
Analysts Strong Buy
Price Target $25.50

Company Profile

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding s...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 380 8342
Address:
2836 Center Port Circle, Pompano Beach, United States
IRISHMIKE1
IRISHMIKE1 Jan. 9 at 4:42 PM
$BSEM Finally broke above $5 !!!
0 · Reply
GlobalInsights
GlobalInsights Jan. 9 at 3:44 PM
$BSEM https://carolinefifemd.com/2026/01/09/no-waste-skin-substitute/
0 · Reply
MarketPro
MarketPro Jan. 9 at 3:32 PM
$BSEM Chart Update
0 · Reply
MarketPro
MarketPro Jan. 7 at 7:18 PM
$BSEM Chart Update
0 · Reply
IRISHMIKE1
IRISHMIKE1 Jan. 7 at 1:21 PM
$BSEM Great run last couple of days! Now how about some news on Uplisting for gods sake!!!
0 · Reply
MarketPro
MarketPro Jan. 6 at 3:22 PM
$BSEM
0 · Reply
Finanz
Finanz Dec. 30 at 2:28 PM
$BSEM BioStem Technologies (OTC: BSEM) reported Q3 2025, generating $10.5 million in net revenue, $0.8 million in GAAP net income, and achieving its seventh consecutive quarter of positive adjusted EBITDA, coming in at $2.7 million.
0 · Reply
ja1234567
ja1234567 Dec. 29 at 12:25 PM
$BSEM unless the 127 per sq is changed it’s all bad news for these companies
0 · Reply
Trader_Guy1
Trader_Guy1 Dec. 27 at 9:28 PM
$BSEM https://www.cms.gov/newsroom/fact-sheets/upcoming-update-final-local-coverage-determinations-lcds-certain-skin-substitutes
0 · Reply
IRISHMIKE1
IRISHMIKE1 Dec. 26 at 12:52 PM
$BSEM Key Sales Figures (as of late 2025 financial reports) Total Annual Revenue (past 12 months): The company reported revenue of approximately $292.21 million over the last 12 months. Recent Quarterly Revenue (Q3 2025): BioStem Technologies reported net revenue of $10.5 million for the third quarter of 2025. Annual Growth: The company experienced significant growth, with revenues growing over 1,700% in the last reported fiscal year to $301.83 million. Profit Margin: The gross profit margin was exceptional at 95.37% in the last financial report.
0 · Reply
Latest News on BSEM
No data available.
IRISHMIKE1
IRISHMIKE1 Jan. 9 at 4:42 PM
$BSEM Finally broke above $5 !!!
0 · Reply
GlobalInsights
GlobalInsights Jan. 9 at 3:44 PM
$BSEM https://carolinefifemd.com/2026/01/09/no-waste-skin-substitute/
0 · Reply
MarketPro
MarketPro Jan. 9 at 3:32 PM
$BSEM Chart Update
0 · Reply
MarketPro
MarketPro Jan. 7 at 7:18 PM
$BSEM Chart Update
0 · Reply
IRISHMIKE1
IRISHMIKE1 Jan. 7 at 1:21 PM
$BSEM Great run last couple of days! Now how about some news on Uplisting for gods sake!!!
0 · Reply
MarketPro
MarketPro Jan. 6 at 3:22 PM
$BSEM
0 · Reply
Finanz
Finanz Dec. 30 at 2:28 PM
$BSEM BioStem Technologies (OTC: BSEM) reported Q3 2025, generating $10.5 million in net revenue, $0.8 million in GAAP net income, and achieving its seventh consecutive quarter of positive adjusted EBITDA, coming in at $2.7 million.
0 · Reply
ja1234567
ja1234567 Dec. 29 at 12:25 PM
$BSEM unless the 127 per sq is changed it’s all bad news for these companies
0 · Reply
Trader_Guy1
Trader_Guy1 Dec. 27 at 9:28 PM
$BSEM https://www.cms.gov/newsroom/fact-sheets/upcoming-update-final-local-coverage-determinations-lcds-certain-skin-substitutes
0 · Reply
IRISHMIKE1
IRISHMIKE1 Dec. 26 at 12:52 PM
$BSEM Key Sales Figures (as of late 2025 financial reports) Total Annual Revenue (past 12 months): The company reported revenue of approximately $292.21 million over the last 12 months. Recent Quarterly Revenue (Q3 2025): BioStem Technologies reported net revenue of $10.5 million for the third quarter of 2025. Annual Growth: The company experienced significant growth, with revenues growing over 1,700% in the last reported fiscal year to $301.83 million. Profit Margin: The gross profit margin was exceptional at 95.37% in the last financial report.
0 · Reply
Georgee23
Georgee23 Dec. 18 at 6:47 PM
$BSEM Love it lol!
0 · Reply
Georgee23
Georgee23 Dec. 18 at 6:05 PM
$BSEM Profit is profit boys!
0 · Reply
Georgee23
Georgee23 Dec. 18 at 5:53 PM
$BSEM Where you at wing man!
0 · Reply
Georgee23
Georgee23 Dec. 18 at 5:13 PM
$BSEM
0 · Reply
Georgee23
Georgee23 Dec. 18 at 5:06 PM
$BSEM Take a look boys!
0 · Reply
IRISHMIKE1
IRISHMIKE1 Dec. 11 at 11:06 PM
$BSEM so after all that I know nothing new and no news on uplifting?! Oh well and keep buying on dips. Cheap enough I can keep doing and hold for the inevitable spike you get with Bio stocks that have real and promising products!
1 · Reply
IRISHMIKE1
IRISHMIKE1 Dec. 11 at 11:03 PM
$BSEM Key Financials (Q3 2025) Revenue: $10.5M GAAP Net Income: $0.8M ($0.05 EPS) Cash & Equivalents: $27.2M In Summary: BioStem Technologies (BSEM) is a high-growth biotech stock with promising financials and trial updates, but its volatile price and mixed technicals mean significant risk alongside potential reward in 202
0 · Reply
IRISHMIKE1
IRISHMIKE1 Dec. 11 at 11:02 PM
$BSEM Cautionary Signals & Mixed Views Technical Weakness: Some technical indicators showed a downward trend in early December 2025, though some momentum indicators suggest potential reversals. Mixed Analyst Consensus: While some see huge gains, the consensus recommendation is often a "Hold," and one intrinsic value analysis suggests the stock is overvalued. High Risk: The stock's rapid rise and pullback indicate volatility, with success tied to clinical trials and Nasdaq listing.
0 · Reply
IRISHMIKE1
IRISHMIKE1 Dec. 11 at 11:02 PM
$BSEM Positive Outlook (Growth & Financials) Strong Growth Projections: Analysts expect substantial EPS growth for 2025, with targets suggesting over 500% upside potential. Healthy Balance Sheet: The company shows little debt compared to significant cash reserves, which increased substantially in 2025. Operational Progress: Positive Q3 2025 results highlighted revenue growth, a clean FDA inspection, and strategic partnerships.
0 · Reply
IRISHMIKE1
IRISHMIKE1 Dec. 11 at 11:01 PM
$BSEM For BSEM (BioStem Technologies), forecasts for 2025 show significant upside potential from some analysts, with targets around $25-$28 based on strong projected EPS growth and solid financials (low debt, high cash)
0 · Reply
IRISHMIKE1
IRISHMIKE1 Dec. 11 at 9:59 PM
$BSEM anyone know if anything is going on with this company. Expected soo much and get left in limbo? Lol
0 · Reply
jimmythefish
jimmythefish Dec. 10 at 2:54 PM
$BSEM https://ir.biostemtechnologies.com/single-news-releases/?webmasterId=104915&storyId=6891883884917831
1 · Reply